Autoimmune Diseases and Gastric Cancer Risk: A Systematic Review and Meta-Analysis

Minkyo Song; Gonzalo Latorre; Danisa Ivanovic-Zuvic; M. Constanza Camargo; Charles S. Rabkin

doi:10.4143/crt.2019.151

Articles

Page Path: HOME > Cancer Res Treat > Volume 51(3); 2019 > Article

Review Article Autoimmune Diseases and Gastric Cancer Risk: A Systematic Review and Meta-Analysis: Minkyo Song, MD, PhD^1,, Gonzalo Latorre, MD², Danisa Ivanovic-Zuvic, MD², M. Constanza Camargo, PhD¹, Charles S. Rabkin, MD¹; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2019;51(3):841-850.
DOI: https://doi.org/10.4143/crt.2019.151
Published online: May 3, 2019

¹Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA

²Department of Internal Medicine, Pontifical Catholic University of Chile, Santiago, Chile

Correspondence: Minkyo Song, MD, PhD Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center Drive, 6E204, Bethesda, MD 20892-9776, USA
Tel: 1-240-276-7985 Fax: 1-240-276-7806 E-mail: minkyo.song@nih.gov

• Received: March 15, 2019 • Accepted: May 1, 2019

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

13,791 Views
542 Download
52 Web of Science
55 Crossref
55 Scopus

Full Article

Download PDF

Abstract

Purpose
Autoimmunity is an alternative etiology of gastric inflammation, the initiating event in the gastric carcinogenic cascade. This mechanism may be an increasingly important cause of gastric cancer with the waning prevalence of its primary etiologic factor, chronic Helicobacter pylori infection.
Materials and Methods
PubMed and EMBASE were searched up to September 2018. Autoimmunity and 96 specific manifestations were considered for associations with gastric cancer risk. Random effects analysis was used to calculate pooled relative risk estimates (RR) and 95% confidence intervals (CI).
Results
We found a total of 52 observational studies representing 30 different autoimmune diseases. Overall, the presence of an autoimmune condition was associated with a gastric cancer pooled RR of 1.37 (95% CI, 1.24 to 1.52). Among the 24 autoimmune conditions with two or more independent reports, nine were significantly associated with increased gastric cancer risk: dermatomyositis (RR, 3.69; 95% CI, 1.74 to 7.79), pernicious anemia (RR, 2.84; 95% CI, 2.30 to 3.50), Addison disease (RR, 2.11; 95% CI, 1.26 to 3.53), dermatitis herpetiformis (RR, 1.74; 95% CI, 1.02 to 2.97; n=3), IgG4-related disease (RR, 1.69; 95% CI, 1.00 to 2.87), primary biliary cirrhosis (RR, 1.64; 95% CI, 1.13 to 2.37), diabetes mellitus type 1 (RR, 1.41; 95% CI, 1.20 to 1.67), systemic lupus erythematosus (RR, 1.37; 95% CI, 1.01 to 1.84), and Graves disease (RR, 1.27; 95% CI, 1.06 to 1.52).
Conclusion
Our analysis documents the wide range of autoimmune diseases associated with gastric cancer. These associations may reflect unreported links between these conditions and autoimmune gastritis. Further studies are warranted to investigate potential causal mechanisms.
Key words: Stomach neoplasms, Autoimmune diseases, Epidemiology, Risk

Introduction

While still the third leading cause of cancer death and the fifth most common cancer worldwide, gastric cancer incidence and mortality have markedly declined over the past few decades [1]. The downward trend has paralleled the decreasing prevalence of Helicobacter pylori infection [2], a major risk factor for this malignancy. However, cancer registration data indicate unexpected increases among recent generations in many parts of the world [3-5], implying etiologic factors other than H. pylori may be responsible [6].

Inflammation is a recognized antecedent of many types of cancer. Autoimmune conditions are important causes of inflammation and appear to have increased in prevalence over recent decades [7], particularly in industrialized populations. An association with gastric cancer has been firmly established for the immune-mediated destruction of the gastric parietal cells, autoimmune gastritis, and its most common clinical manifestation, pernicious anemia [8]. Other autoimmune conditions have been variably linked with gastric cancer risk, perhaps as a consequence of their frequent co-occurrence with autoimmune gastritis or, alternatively, through some systemic effect(s) that remains to be elucidated. To better understand the role of autoimmunity in gastric carcinogenesis, we undertook a systematic review and meta-analysis of observational studies addressing associations of autoimmune diseases and gastric cancer risk.

Materials and Methods

1. Search strategy and inclusion criteria

PubMed (U.S. National Library of Medicine, Bethesda, MD) and EMBASE (Elsevier B.V., Amsterdam, The Netherlands) search engines were used to identify published articles on gastric cancer risk in patients with autoimmune diseases by combining terms for (1) “stomach cancer” with synonyms, (2) “autoimmune disease” with synonyms or 96 specific autoimmune diseases with synonyms, and (3) “risk” with synonyms. The search strategy syntax was as follows: (1) ['stomach cancer'/exp OR 'cancer, stomach' OR 'gastric cancer' OR 'stomach cancer' OR 'gastric neoplasm'], AND (2) ['autoimmune disease'/exp OR 'auto immune disease' OR 'auto immunologic disease' OR 'auto-immune disorder' OR 'auto-immune disorders' OR 'autoaggression, immune' OR 'autoaggressive disease' OR 'autoantibody disease' OR 'autoimmune disease' OR 'autoimmune diseases' OR 'autoimmune disorder' OR 'autoimmune disorders' OR 'autoimmune disturbance' OR 'autoimmune pathology' OR 'autoimmune disease' OR 'autoimmunologic disease' OR (96 autoimmune diseases with their synonyms)], AND (3) ['risk' /exp OR 'risk' OR 'risk hypothesis' OR 'cancer risk'/exp OR 'cancer risk' OR 'risk factor'/exp OR 'relative risk' OR 'risk factor' OR 'risk factors']. The list of specific autoimmune diseases was generated by combining the 92 terms listed as autoimmune diseases in the National Library of Medicine controlled vocabulary thesaurus for indexing articles, Medical Subject Headings (MeSH), and the EMBASE equivalent, Emtree, with pernicious anemia, autoimmune gastritis, celiac disease and primary biliary cirrhosis. The full list of autoimmune conditions and their syntax can be found in S1 and S2 Tables.

Literature searches were conducted for database entries through September 30, 2018, without restriction on language or article type. Reference lists of retrieved articles were also checked for additional papers that were not identified by our database search strategy. Two investigators (G.L. and D.I.Z.) independently reviewed the articles for relevance and availability of basic information, with any disagreement resolved by a third reviewer (M.C.C.). After the initial scanning of titles and abstracts, full text of selected articles was obtained for data extraction. Articles retained for the final analysis were those with either case-counts or risk estimates reported as standardized incidence ratio (SIR), standardized mortality ratio, incident rate ratio, adjusted rate ratio, hazard ratio, relative risk (RR), or odds ratio. The following data were extracted as available: first author, year of publication, study design, study period, sex, country of origin, regional group, type of autoimmune disease, sample size, tumor subsite, risk estimates and their corresponding 95% confidence intervals (CI), and adjusted confounders (S3 Table). The methodological quality of each selected publication was evaluated using the Newcastle-Ottawa Scale for cohort and case-control studies, summarized in S4 and S5 Tables, respectively [9]. We considered a study scoring ≥ 7 to be high quality. Sensitivity analysis restricting to high quality studies was conducted where applicable. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for reporting [10].

2. Statistical analyses

Summary estimates preferentially included the associations for total populations in a study rather than a subgroup (e.g., males and females combined rather than single sex, and gastric cancer overall rather than separate anatomical subsites). If there was no overall value presented, associations for subgroups (e.g., males and females) were included as separate studies. Standardized ratios or adjusted rates were used when available, but the association measures were derived based on the study design when only observed and expected case counts were provided. Summary risk estimates were calculated if there were two or more studies published for a given autoimmune condition. For selected diseases with common features, we also estimated associations for the combined group. We also evaluated associations with “alimentary tract involving diseases,” following previous reports [11,12].

Random-effects regression models were used to metaanalyze the summary risk estimates as RR with corresponding 95% CIs [13]. Heterogeneity among studies was assessed with Cochran’s Q test and Higgin’s I² statistics [14]. Publication bias was evaluated by Begg’s funnel plots and Egger’s tests [15]. Funnel plot asymmetry was examined with the trim and fill method of Duval and Tweedie [16]. To explore sources of heterogeneity, meta-regressions were conducted according to study design (case-control, retrospective cohort, or prospective cohort), year of publication (< 2,000 vs. ≥ 2,000), geographic area (Asia, Europe, USA, or multiple), sex (male, female or combined) and tumor subsite (cardia vs. noncardia). Statistical analyses were conducted using STATA SE 15 software (StataCorp., College Station, TX). All statistical tests were two-sided and p-values of < 0.05 were considered statistically significant.

Results

A total of 1,134 articles were identified after removing the duplicates through the database search (S6 Fig.). Of these, 964 articles were excluded as irrelevant on the basis of title or abstract. The remaining 170 articles were reviewed for fulltext as well as their references, and finally 52 studies with relevant and extractable information were included for metaanalysis. The full list of included articles and the corresponding data items are presented in S3 Table. There were 12 prospective cohort studies, 36 retrospective cohort studies and four case-control studies. Most of the studies were conducted in Western populations (30 European studies, six in the United States and one multi-country effort). There were 15 studies from Asia. Forty-one of the 52 papers were judged high quality. A total of 45 different autoimmune conditions were reported in these studies, amongst which 30 conditions had two or more studies for pooling. However, six of these 30 included studies with zero cases and insufficient information (such as expected cancers) for deriving risk estimates.

Table 1 lists associations of 24 autoimmune conditions with gastric cancer risk. The strongest associations were observed for dermatomyositis (RR, 3.69; 95% CI, 1.74 to 7.79), pernicious anemia (RR, 2.84; 95% CI, 2.30 to 3.50), and Addison disease (RR, 2.11; 95% CI, 1.26 to 3.53). Other autoimmune conditions that were statistically significantly associated with gastric cancer risk were dermatitis herpetiformis, IgG4-related disease, primary biliary cirrhosis, diabetes mellitus type 1 (T1DM), and systematic lupus erythematosus (SLE). Among disease groups, statistically significant increases were observed for polymyositis/dermatomyositis combined with RR 2.09 (95% CI, 1.04 to 4.20), polymyalgia rheumatica/giant cell arteritis with RR 1.33 (95% CI, 1.16 to 1.52) and autoimmune thyroid disease with RR 1.31 (95% CI, 1.12 to 1.54). Multiple sclerosis was the only condition associated with statistically significant decreased risk, RR 0.64 (95% CI, 0.45 to 0.92). Excluding pernicious anemia, pooled risk estimates for alimentary tract-involving and non-alimentary autoimmune conditions were 1.18 (95% CI, 1.04 to 1.33) and 1.21 (95% CI, 1.10 to 1.34), respectively. Autoimmune diseases that involve endocrine glands, which include Addison disease, autoimmune thyroiditis and T1DM had pooled RR 1.42 (95% CI, 1.25 to 1.61), whereas autoimmune nonendocrine diseases other than pernicious anemia had pooled RR 1.15 (95% CI, 1.06 to 1.26; p_{heterogeneity}=0.008). Considering all reports combined, having any autoimmune condition was associated with statistically significant pooled RR 1.37 (95% CI, 1.24 to 1.52).

There were no reports of gastric cancer with pernicious anemia in the studies from Asia. Considering all other autoimmune diseases combined, the summary RR for gastric cancer was 1.08 (95% CI, 0.90 to 1.29) in studies from Asia compared to 1.24 (95% CI, 1.14 to 1.34) in studies from non-Asian countries (p_{heterogeneity}=0.005).

Funnel plots were symmetric for all conditions. Imputation of hypothetical missing results by the trim and fill method did not alter the estimated associations by more than 20% with the exception of immune thrombocytopenic purpura for which change in RR was 56%.

Pernicious anemia, T1DM and SLE each had more than 5 studies for analysis and are displayed separately as forest plots in Figs. 1-3.

There was marked heterogeneity among the 14 studies of the association of pernicious anemia with gastric cancer overall, indicated by I² =82.4% and p-value of < 0.001 (Fig. 1) [11,12,17-28]. Sensitivity analyses restricted to cohort studies (n=13; RR, 2.94; 95% CI, 2.37 to 3.65) and high quality studies (n=12; RR, 2.70; 95% CI, 2.15 to 3.40) were similar to our overall pooled RR.

A low heterogeneity among studies was observed in the meta-analysis of T1DM (n=9) association with I² =35.7% and p=0.13 (Fig. 2) [11,29-34]. For the four studies with sex information, the association was significantly greater in females (RR, 1.77; 95% CI, 1.51 to 2.07) compared to males (RR, 1.19; 95% CI, 1.03 to 1.39) (p_{heterogeneity} < 0.001).

Gastric cancer RR with SLE showed low heterogeneity among studies (n=6) with I² =17.6% and p=0.303 (Fig. 3) [11,12,35-38].

The 15 conditions with only one study report and the additional six with insufficient information for pooling are summarized in Table 2. Apart from those diseases mentioned in Table 1, statistically significant associations were reported for myasthenia gravis (RR, 1.38; 95% CI, 1.14 to 1.65) [11] and alopecia areata (RR, 0.46; 95% CI, 0.33 to 0.65) [39].

Discussion

This is the first comprehensive review of autoimmune conditions in gastric cancer risk. Our meta-analysis identified significant associations for autoimmunity overall and for several specific conditions. We extended the known association of pernicious anemia with greater statistical power. By pooling all available evidence to date, we found novel associations for some autoimmune diseases which showed inconsistent or null results in individual studies.

There was a modest increase of gastric cancer risk across all autoimmune conditions combined. Autoimmunity could be linked with gastric carcinogenesis through different potential pathways. Many of the conditions associated with gastric cancer in this study, such as autoimmune thyroiditis, T1DM, vitiligo, and Addison disease, frequently cooccur with pernicious anemia, which has a direct mechanistic interpretation through its pathological correlate, autoimmune gastritis. Indeed, the overall association of autoimmune conditions with gastric cancer was significantly weaker in studies from Asia than from other parts of the world, consistent with the relatively lower incidence of pernicious anemia in Asian populations [40]. Alternatively, autoimmunity might exacerbate H. pylori–driven gastritis in the absence of autoimmune gastritis per se. For either of these scenarios, the etiologic contributions of other components of the gastric microbiome remains to be determined.

In the study of 4.5 million U.S. male veterans [12], autoimmune diseases with alimentary tract involvement were associated with an increased risk of alimentary tract cancers, including gastric cancer, whereas conditions without alimentary tract involvement generally were not significantly associated. Using the same definition of alimentary tract involvement and excluding pernicious anemia, we found no difference in gastric cancer risk between alimentary tractinvolving versus all other conditions. On the other hand, when we grouped the non-pernicious anemia autoimmune conditions based on endocrine gland involvement, gastric cancer risk was significantly higher for autoimmune endocrine diseases than for the remainder. Given that pernicious anemia results from destruction of secretory parietal cells, these observations reinforce the intriguing concept that the autoimmune component of gastric carcinogenesis is more closely linked to glandular targets than to the alimentary tract per se.

Epidemiologic evidence for an autoimmune contribution to gastric carcinogenesis is not limited to studies of patients with personal history of autoimmune conditions. In a study linking the Swedish Multigeneration Register and the Swedish Cancer Register, family history of autoimmune disease in siblings was associated with noncardia gastric cancer with SIR 1.36 (95% CI, 1.22 to 1.52) [41]. On the other hand, autoimmune disease in spouses was not associated. Taken together, these observations favor an underlying basis that is related to either genes or childhood environment (shared by siblings), rather than adult exposures (shared by spouses).

Although based on only a limited number of studies, multiple sclerosis and alopecia areata showed significant inverse association with gastric cancer. Both of these diseases share similar characteristics of increased T helper type 1 immune activation and altered cytokine levels which were postulated to have inhibitory effects on carcinogenesis [12,39].

Our study has some limitations and thus the results should be interpreted with caution. First, like many other studies investigating patient populations, the effect of treatments for autoimmune conditions could not be fully addressed. Immunosuppressive medications or immunomodulatory drugs, such as steroids, cytotoxic agents and nonsteroidal antiinflammatory drugs, may themselves affect gastric carcinogenesis. There may also be decreased medical surveillance in severely debilitating diseases which might explain the inverse association for multiple sclerosis. Second, despite our attempt to include all available literature, only a relatively small number of studies met inclusion criteria, and many autoimmune diseases had insufficient data for a meta-analysis. However, autoimmune diseases with small numbers of studies and comparisons that lack statistical significance should not be interpreted as evidence against association. Third, most of the studies were based in Western populations and prevalence of many autoimmune diseases varies across race/ethnicity and geographical location, limiting generalizability of the pooled risk estimates. Fourth, autoimmune diseases are underdiagnosed conditions, and some degree of misclassification of exposure is likely. Such nondifferential misclassification would tend to attenuate true associations between autoimmune disease and gastric cancer. Fifth, as in any meta-analysis, possible publication bias is a concern although we did not find evidence for missing information with trim and fill correction. Sixth, clinical assessment of autoimmune diseases may vary across the studies. Lastly, gastric cancer risk factors such as H. pylori infection or smoking were not taken into account in many of these studies.

Despite the above limitations, our study has many strengths. Our systematic review is the first attempt to comprehensively summarize current evidence associating autoimmunity with gastric cancer risk. By pooling small studies, we were able to increase power for novel findings. Most of the studies were prospective investigations of incident gastric cancer, minimizing the possibility of reverse causality. Lastly, most of the included studies were classified as good quality.

The rarity of autoimmune diseases with their characteristic predominance in females, developed countries and Western populations, combined with the opposite profile for gastric cancer burden (males, under-developed countries, Asians), may have hampered recognition of the links between these entities. Future studies are warranted to investigate these associations in different races and ethnic groups, by anatomical subsite or tumor histology, and with consideration of treatment effects. Moreover, our findings may have important clinical and public health implications. The apparent increases in autoimmune disease and the newly recognized relation to gastric cancer risk have important implications for predicting future cancer incidence and planning strategies for control and prevention.

Electronic Supplementary Material

Supplementary materials are available at Cancer Research and Treatment website (https://www.e-crt.org).

crt-2019-151-suppl1.pdf

crt-2019-151-suppl2.pdf

crt-2019-151-suppl3.pdf

crt-2019-151-suppl4.pdf

crt-2019-151-suppl5.pdf

crt-2019-151-suppl6.pdf

crt-2019-151-suppl7.pdf

crt-2019-151-suppl8.pdf

NOTES

Conflict of interest relevant to this article was not reported.

Acknowledgements

This study was supported by the Intramural Research Program, Division of Cancer Epidemiology and Genetics, US National Cancer Institute, National Institutes of Health, Department of Health and Human Services. The authors thank Nancy Terry, Biomedical Librarian at the U.S. NIH Library for her help with reviewing the search strategies.

Fig. 1.

Random effects summary relative risk (RR) and 95% confidence interval (CI) for gastric cancer among individuals with pernicious anemia [11,12,17-28].

Fig. 2.

Random effects summary relative risk (RR) and 95% confidence interval (CI) for gastric cancer among individuals with diabetes mellitus type 1 [11,29-34].

Fig. 3.

Random effects summary relative risk (RR) and 95% confidence interval (CI) for gastric cancer among individuals with systemic lupus erythematosus [11,12,35-37].

Table 1.

Random effects summary relative risk (RR) and 95% confidence interval (CI) of gastric cancer for persons with autoimmune disease

Autoimmune disease	Studies included for analysis	Gastric cancer cases	Summary RR	95% CI	Cochran Q statistic (p_{heterogeneity})	Higgin’s I² statistics	Egger test p-value	Studies imputed by trim and fill
Individual diagnoses
Addison disease	2	20	2.11	1.26-3.53	1.26 (0.26)	20.5	-	0
Amyotrophic lateral sclerosis	2	13	0.93	0.53-1.62	0.01 (0.93)	0	-	1
Ankylosing spondylitis	2	34	1.01	0.72-1.42	0.21 (0.65)	0	-	0
Celiac disease	7	80	1.36	0.87-2.13	18.53 (< 0.001)	73	0.59	0
Chronic rheumatic heart disease	2	184	1.19	0.86-2.13	8.28 (< 0.001)	87.9	-	0
Crohn disease	3	60	0.87	0.68-1.12	0.24 (0.89)	0	0.91	0
Dermatitis herpetiformis	3	13	1.74	1.02-2.97	1.07 (0.59)	0	0.07	2
Dermatomyositis	4	11^a)	3.69	1.74-7.79	5.10 (0.16)	41.2	0.66	2^b)
Diabetes mellitus, type 1	9	256^a)	1.41	1.20-1.67	12.45 (0.13)	35.7	0.89	0^b)
Graves disease	3	120	1.27	1.06-1.52	0.81 (0.67)	0	0.09	0
IgG4-related disease	2	6	1.69	1.00-2.87	0.58 (0.45)	0	-	1
Immune thrombocytopenic purpura	2	15	1.32	0.26-6.70	9.03 (< 0.001)	88.9	-	1
Multiple sclerosis	2	30	0.64	0.45-0.92	0.47 (0.50)	0	-	0
Pernicious anemia	14	2,688	2.84	2.30-3.50	73.98 (< 0.001)	82.4	0.32	0^b)
Polymyositis	2	2	0.82	0.12-5.55	2.30 (0.13)	56.6	-	0
Polymyositis/Dermatomyositis	2	7	1.15	0.16-8.25	4.42 (0.04)	77.4	-	0
Primary biliary cirrhosis	4	28	1.64	1.13-2.37	0.32 (0.96)	0	0.66	1
Psoriasis	2	128	1.18	0.98-1.14	0.58 (0.45)	0	-	1
Rheumatoid arthritis	10	388	0.93	0.82-1.07	15.78 (0.07)	43.0	0.38	1
Sarcoidosis	2	36	1.00	0.41-2.44	3.75 (0.05)	73.4	-	0
Sjögren syndrome	4	27^a)	1.33	0.99-1.79	3.15 (0.37)	4.6	0.05	1
Systemic lupus erythematosus	6	35^a)	1.37	1.01-1.84	4.85 (0.30)	17.6	0.12	0^b)
Systemic sclerosis	5	12^a)	0.93	0.58-1.48	0.56 (0.97)	0	0.74	0
Ulcerative colitis	3	45	0.94	0.70-1.26	0.95 (0.62)	0	0.27	0
Grouped diagnoses^c)
Autoimmune thyroid disease		163	1.31	1.12-1.54	3.84 (0.43)	0	0.77	0
Inflammatory bowel disease		105^a)	0.89	0.74-1.07	1.19 (0.93)	0	0.34	0
Polymyositis/Dermatomyositis		20^a)	2.09	1.04-4.20	17.59 (0.01)	60.2	0.10	0
Polymyalgia rheumatica/Giant cell arteritis		202	1.33	1.16-1.52	0.78 (0.38)	0	-	1
Vasculitides		38	1.03	0.75-1.41	1.89 (0.60)	0	0.84	0
Alimentary tract involving autoimmune diseases other than pernicious anemia		391^a)	1.18	1.04-1.33	60.16 (0.01)	36.8	0.86	0^b)
Non-alimentary tract involving autoimmune diseases		1,736^a)	1.21	1.10-1.34	182.77 (< 0.001)	67.7	0.43	10^b)
Endocrine organ autoimmune diseases		521^a)	1.42	1.25-1.61	21.39 (0.13)	29.9	0.65	0^b)
Non-endocrine organ autoimmune diseases other than pernicious anemia		1,607^a)	1.15	1.06-1.26	202.72 (< 0.001)	59.6	0.51	9^b)
Any autoimmune disease other than pernicious anemia		627^a)	1.20	1.11-1.30	243.13 (< 0.001)	59.7	0.60	9^b)
Any autoimmune disease		3,315^a)	1.37	1.24-1.52	685.72 (< 0.001)	83.7	0.18	0^b)

^a) One or more studies did not provide number of cases,

^b) Retained significance after trim and fill imputation,

^c) Grouped diagnoses definitions (numbers of studies included): autoimmune thyroid disease: autoimmune thyroid disease (1), Graves disease (3), Hashimoto/hypothyroidism (1); inflammatory bowel disease: Crohn disease (3), inflammatory bowel disease (1), ulcerative colitis (3); polymyositis/dermatomyositis: dermatomyositis (2), polymyositis (1), polymyositis/dermatomyositis (1); polymyalgia rheumatica/giant cell arteritis: polymyalgia rheumatica (1), polymyalgia rheumatica/giant cell arteritis (1); vasculitides: antineutrophil cytoplasmic antibody associated vasculitis (1), polyarteritis nodosa (1), Takayasu arteritis (1), Wegener granulomatosis (1); alimentary tract involving autoimmune diseases: ankylosing spondylitis (2), celiac disease (7), Crohn disease (3), discoid lupus erythematosus (1), immune thrombocytopenic purpura (2), inflammatory bowel disease (1), localized scleroderma (1), pernicious anemia (16), primary biliary cirrhosis (4), sarcoidosis (2), Sjögren syndrome (4), systemic lupus erythematosus (7), systemic sclerosis (5), ulcerative colitis (3); endocrine organ autoimmune diseases: Addison disease (2), autoimmune thyroid disease (5), diabetes mellitus, type 1 (11); any autoimmune disease: includes all diagnoses listed in Tables 1 or 2.

Table 2.

Reported associations of gastric cancer with autoimmune diseases from single studies

Disease	Exposed persons	Gastric cancer persons	Reported association
Autoimmune pancreatitis type 1	109	3	1.35 (0.03-2.66)
ANCA associated vasculitis: GPA and MPA^a)	203	1	2.37 (0.06-13.2)
Alopecia areata	12,199	39	0.46 (0.33-0.65)
Autoimmune hemolytic anemia	NR	6	1.10 (0.46-2.65)
Autoimmune thyroid disease^a)	23	17	3.16 (1.14-8.71)
Behçet disease	2,860	11	1.66 (0.83-2.99)
	1,620	0	NR
Discoid lupus erythematosus	NR	9	0.95 (0.48-1.90)
Hashimoto/hypothyroidism^a)	10,682	26	1.34 (0.87-1.96)
Inflammatory bowel disease^a)	2,853	NR	0.53 (0.13-2.11)
Kawasaki disease	3,463	0	NR
Localized scleroderma	3,128	11	1.56 (0.70-2.55)
	NR	0	NR
Membranous nephropathy	161	1	2.74 (0.07-15.3)
Myasthenia gravis	17,974	117	1.38 (1.14-1.65)
	NR	0	NR
Polyarteritis nodosa	12,046	35	1.02 (0.71-1.42)
	NR	0	NR
Polymyalgia rheumatica^a)	14,745	63	1.45 (1.11-1.85)
	NR	0	NR
Polymyalgia rheumatica/Giant cell arteritis^a)	35,918	139	1.27 (1.07-1.50)
Reactive arthritis	NR	0	NR
Rheumatic fever	3,458	16	1.50 (0.86-2.44)
	NR	0	NR
Takayasu arteritis	180	1	1.4 (0.0-7.3)
Vasculitis excluding Kawasaki disease	644	0	NR
Wegener granulomatosis^a)	345	1	0.45 (0.0-2.59)

ANCA, antineutrophil cytoplasmic antibody; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiits; NR, not reported.

^a) Also included in Table 1 grouped diagnoses.

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. Article PubMed
2. Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153:420–9. Article PubMed
3. Anderson WF, Rabkin CS, Turner N, Fraumeni JF Jr, Rosenberg PS, Camargo MC. The changing face of noncardia gastric cancer incidence among US non-Hispanic whites. J Natl Cancer Inst. 2018;110:608–15. Article PubMed PMC PDF
4. Luo G, Zhang Y, Guo P, Wang L, Huang Y, Li K. Global patterns and trends in stomach cancer incidence: age, period and birth cohort analysis. Int J Cancer. 2017;141:1333–44. Article PubMed
5. Eom BW, Jung KW, Won YJ, Yang H, Kim YW. Trends in gastric cancer incidence according to the clinicopathological characteristics in Korea, 1999-2014. Cancer Res Treat. 2018;50:1343–50. Article PubMed PMC PDF
6. Song M, Rabkin CS, Camargo MC. Gastric cancer: an evolving disease. Curr Treat Options Gastroenterol. 2018;16:561–9. Article PubMed PMC PDF
7. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med. 2002;347:911–20. Article PubMed
8. Toh BH. Diagnosis and classification of autoimmune gastritis. Autoimmun Rev. 2014;13:459–62. Article PubMed
9. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]. Ottawa: Ottawa Hospital Research Institute; 2018. [cited 2018 Oct 5]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
10. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:e1–34. Article PubMed
11. Hemminki K, Liu X, Ji J, Sundquist J, Sundquist K. Autoimmune disease and subsequent digestive tract cancer by histology. Ann Oncol. 2012;23:927–33. Article PubMed PDF
12. Landgren AM, Landgren O, Gridley G, Dores GM, Linet MS, Morton LM. Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans. Cancer. 2011;117:1163–71. Article PubMed
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88. Article PubMed
14. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58. Article PubMed
15. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34. Article PubMed PMC
16. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63. Article PubMed
17. Blackburn EK, Callender ST, Dacie JV, Doll R, Girdwood RH, Mollin DL, et al. Possible association between pernicious anaemia and leukaemia: a prospective study of 1,625 patients with a note on the very high incidence of stomach cancer. Int J Cancer. 1968;3:163–70. Article PubMed
18. Brinton LA, Gridley G, Hrubec Z, Hoover R, Fraumeni JF Jr. Cancer risk following pernicious anaemia. Br J Cancer. 1989;59:810–3. Article PubMed PMC PDF
19. Eriksson S, Clase L, Moquist-Olsson I. Pernicious anemia as a risk factor in gastric cancer. The extent of the problem. Acta Med Scand. 1981;210:481–4. Article PubMed
20. Hsing AW, Hansson LE, McLaughlin JK, Nyren O, Blot WJ, Ekbom A, et al. Pernicious anemia and subsequent cancer: a population-based cohort study. Cancer. 1993;71:745–50. Article PubMed
21. Kokkola A, Sjoblom SM, Haapiainen R, Sipponen P, Puolakkainen P, Jarvinen H. The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anaemia: a prospective follow-up study. Scand J Gastroenterol. 1998;33:88–92. Article PubMed
22. Mellemkjaer L, Gridley G, Moller H, Hsing AW, Linet MS, Brinton LA, et al. Pernicious anaemia and cancer risk in Denmark. Br J Cancer. 1996;73:998–1000. Article PubMed PMC PDF
23. Mosbech J, Videbaek A. Mortality from and risk of gastric carcinoma among patients with pernicious anaemia. Br Med J. 1950;2:390–4. Article PubMed PMC
24. Murphy G, Dawsey SM, Engels EA, Ricker W, Parsons R, Etemadi A, et al. Cancer risk after pernicious anemia in the US elderly population. Clin Gastroenterol Hepatol. 2015;13:2282–9. e1-4Article PubMed PMC
25. Schafer LW, Larson DE, Melton LJ 3rd, Higgins JA, Zinsmeister AR. Risk of development of gastric carcinoma in patients with pernicious anemia: a population-based study in Rochester, Minnesota. Mayo Clin Proc. 1985;60:444–8. Article PubMed
26. Jorgensen J. The mortality among patients with pernicious anemia in Denmark and the incidence of gastric carcinoma among the same. Acta Med Scand. 1951;139:472–81. Article PubMed
27. Vannella L, Lahner E, Osborn J, Bordi C, Miglione M, Delle Fave G, et al. Risk factors for progression to gastric neoplastic lesions in patients with atrophic gastritis. Aliment Pharmacol Ther. 2010;31:1042–50. Article PubMed
28. Berkson J, Butt HR, Comfort MW. Occurrence of gastric cancer in persons with achlorhydria and with pernicious anemia. Proc Staff Meet Mayo Clin. 1956;31:583–96. PubMed
29. Carstensen B, Read SH, Friis S, Sund R, Keskimaki I, Svensson AM, et al. Cancer incidence in persons with type 1 diabetes: a five-country study of 9,000 cancers in type 1 diabetic individuals. Diabetologia. 2016;59:980–8. Article PubMed PMC PDF
30. Harding JL, Shaw JE, Peeters A, Cartensen B, Magliano DJ. Cancer risk among people with type 1 and type 2 diabetes: disentangling true associations, detection bias, and reverse causation. Diabetes Care. 2015;38:264–70. Article PubMed
31. Valent F. Diabetes mellitus and cancer of the digestive organs: an Italian population-based cohort study. J Diabetes Complications. 2015;29:1056–61. Article PubMed
32. Swerdlow AJ, Laing SP, Qiao Z, Slater SD, Burden AC, Botha JL, et al. Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study. Br J Cancer. 2005;92:2070–5. Article PubMed PMC PDF
33. O'Mara BA, Byers T, Schoenfeld E. Diabetes mellitus and cancer risk: a multisite case-control study. J Chronic Dis. 1985;38:435–41. Article PubMed
34. Hsu PC, Lin WH, Kuo TH, Lee HM, Kuo C, Li CY. A population-based cohort study of all-cause and site-specific cancer incidence among patients with type 1 diabetes mellitus in Taiwan. J Epidemiol. 2015;25:567–73. Article PubMed PMC
35. Bernatsky S, Ramsey-Goldman R, Labrecque J, Joseph L, Boivin JF, Petri M, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013;42:130–5. Article PubMed PMC
36. Chang SH, Park JK, Lee YJ, Yang JA, Lee EY, Song YW, et al. Comparison of cancer incidence among patients with rheumatic disease: a retrospective cohort study. Arthritis Res Ther. 2014;16:428.Article PubMed PMC PDF
37. Yu KH, Kuo CF, Huang LH, Huang WK, See LC. Cancer risk in patients with inflammatory systemic autoimmune rheumatic diseases: a nationwide population-based dynamic cohort study in Taiwan. Medicine (Baltimore). 2016;95:e3540Article PubMed PMC
38. Dreyer L, Faurschou M, Mogensen M, Jacobsen S. High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort. Arthritis Rheum. 2011;63:3032–7. Article PubMed
39. Seo HM, Han SS, Kim JS. Cancer risks among patients with alopecia areata: a population-based case-control study in Korea. J Am Acad Dermatol. 2018;78:209–11. Article PubMed
40. Stabler SP, Allen RH. Vitamin B12 deficiency as a worldwide problem. Annu Rev Nutr. 2004;24:299–326. Article PubMed
41. Ji J, Sundquist J, Sundquist K. Family history of autoimmune diseases and risk of gastric cancer: a national cohort study. Eur J Cancer Prev. 2018;27:221–6. Article PubMed

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Is autoimmunity associated with the development of premalignant oral conditions and the progression to oral squamous cell carcinoma?: A literature review
Jeong-Hyun Kang, Seok Woo Hong
Journal of Stomatology, Oral and Maxillofacial Surgery.2025; 126(5): 102139. CrossRef
Antinuclear Positivity and Malignant Transformation Potential of Oral Potentially Malignant Disorder
Seok Woo Hong, Jeong‐Hyun Kang
Oral Diseases.2025; 31(4): 1107. CrossRef
Helicobacter pylori and rheumatoid arthritis: Investigation of relation from traditional Chinese medicine
Hua Zhao, Yige Wang, Jiahui Ren
Microbial Pathogenesis.2025; 199: 107239. CrossRef
Beyond metaplasia: unraveling the complex pathogenesis of autoimmune atrophic gastritis and its implications for gastric cancer risk
Tai Zhang, Xudong Tang
QJM: An International Journal of Medicine.2025;[Epub] CrossRef
Autoimmune diseases and risk of gastrointestinal cancer: an umbrella review of meta-analyses of observational studies
Xiao Bai, Yunran Guo, Xinmao Zhu, Dongqiu Dai
International Journal of Surgery.2025; 111(2): 2273. CrossRef
Risk relationship between six autoimmune diseases and malignancies: An umbrella review
Ping Yang, Qinguo Liu, Hengheng Zhang, Meijie Wu, Jiuda Zhao, Guoshuang Shen, Yi Zhao
Autoimmunity Reviews.2025; 24(5): 103779. CrossRef
Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG) and European Society of Pathology (ESP) Guideli
Mário Dinis-Ribeiro, Diogo Libânio, Hugo Uchima, Manon C.W. Spaander, Jan Bornschein, Tamara Matysiak-Budnik, Georgios Tziatzios, João Santos-Antunes, Miguel Areia, Nicolas Chapelle, Gianluca Esposito, Gloria Fernandez-Esparrach, Lumir Kunovsky, Mónica Ga
Endoscopy.2025; 57(05): 504. CrossRef
Therapy and mechanism of natural polysaccharides for atopic dermatitis treatment
Wenjie Wang, Lijun Shao, Xiao Jiang, Qiulu Chu, Jian Xiao, Shufang Wu
Food Science and Human Wellness.2025; 14(5): 9250101. CrossRef
Implementation of the updated Sydney system biopsy protocol improves the diagnostic yield of gastric preneoplastic conditions: Results from a real-world study
Gonzalo Latorre, José Ignacio Vargas, Shailja C. Shah, Danisa Ivanovic-Zuvic, Pablo Achurra, Martín Fritzsche, Jai-Sen Leung, Bernardita Ramos, Elisa Jensen, Javier Uribe, Isabella Montero, Vicente Gandara, Camila Robles, Miguel Bustamante, Felipe Silva,
Gastroenterología y Hepatología.2024; 47(8): 793. CrossRef
Pathology and Clinical Relevance of Gastric Epithelial Dysplasia
Tetsuo Ushiku, Gregory Y. Lauwers
Gastroenterology Clinics of North America.2024; 53(1): 39. CrossRef
RE.GA.IN.: the Real-world Gastritis Initiative–updating the updates
Massimo Rugge, Robert M Genta, Peter Malfertheiner, Mario Dinis-Ribeiro, Hashem El-Serag, David Y Graham, Ernst J Kuipers, Wai Keung Leung, Jin Young Park, Theodore Rokkas, Christian Schulz, Emad M El-Omar
Gut.2024; : gutjnl-2023-331164. CrossRef
Autoimmunity and epithelial dysplasia in patients with oral lichenoid diseases
Jeong‐Hyun Kang, Ji Eun Kwon
Oral Diseases.2024; 30(8): 5091. CrossRef
Ex Vivo-Generated Tolerogenic Dendritic Cells: Hope for a Definitive Therapy of Autoimmune Diseases
Jonny, Enda Cindylosa Sitepu, Chairul A. Nidom, Soetojo Wirjopranoto, I. Ketut Sudiana, Arif N. M. Ansori, Terawan Agus Putranto
Current Issues in Molecular Biology.2024; 46(5): 4035. CrossRef
Autoimmune conditions and gastric cancer risk in a population-based study in the United Kingdom
John D. Murphy, Shahinaz M. Gadalla, Lesley A. Anderson, Charles S. Rabkin, Chris R. Cardwell, Minkyo Song, M. Constanza Camargo
British Journal of Cancer.2024; 131(1): 138. CrossRef
Non-Invasive Markers for the Detection of Gastric Precancerous Conditions
Marcin Romańczyk, Malgorzata Osmola, Alexander Link, Amaury Druet, Caroline Hémont, Jerome Martin, Nicolas Chapelle, Tamara Matysiak-Budnik
Cancers.2024; 16(12): 2254. CrossRef
Implementation of the updated Sydney system biopsy protocol improves the diagnostic yield of gastric preneoplastic conditions: Results from a real-world study
Gonzalo Latorre, José Ignacio Vargas, Shailja C. Shah, Danisa Ivanovic-Zuvic, Pablo Achurra, Martín Fritzsche, Jai-Sen Leung, Bernardita Ramos, Elisa Jensen, Javier Uribe, Isabella Montero, Vicente Gandara, Camila Robles, Miguel Bustamante, Felipe Silva,
Gastroenterología y Hepatología (English Edition).2024; 47(8): 793. CrossRef
Recurrent Gastric Cancer Initially Presenting with Dysphagia induced by Idiopathic Inflammatory Myositis: A Case Report
Che-Hao Chang, Li-Chun Lu
Journal of Cancer Research and Practice.2024; 11(4): 141. CrossRef
Morphological characteristics of autoimmune gastritis
A.S. Tertychnyy, N.V. Pachuashvili, D.D. Protsenko, D.P. Nagornaya, A.B. Kazumova
Russian Journal of Archive of Pathology.2024; 86(6): 15. CrossRef
Autoimmune gastritis: long-term natural history in naïveHelicobacter pylori-negative patients
Massimo Rugge, Ludovica Bricca, Stefano Guzzinati, Diana Sacchi, Marco Pizzi, Edoardo Savarino, Fabio Farinati, Manuel Zorzi, Matteo Fassan, Angelo Paolo Dei Tos, Peter Malfertheiner, Robert M Genta, David Y Graham
Gut.2023; 72(1): 30. CrossRef
Risk factors for gastric cancer: A comprehensive analysis of observational studies
Yuqing Hui, Chunyi Tu, Danlei Liu, Huijie Zhang, Xiaobing Gong
Frontiers in Public Health.2023;[Epub] CrossRef
Incidence of Gastric Neoplasms Arising from Autoimmune Metaplastic Atrophic Gastritis: A Systematic Review and Case Reports
Chuyan Chen, Yi Yang, Peng Li, Haiyi Hu
Journal of Clinical Medicine.2023; 12(3): 1062. CrossRef
Metachronous tumors of the stomach in a patient with autoimmune gastritis
N.V. Pachuashvili, D.P. Nagornaya, A.S. Tertychnyi
Russian Journal of Archive of Pathology.2023; 85(1): 57. CrossRef
Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention
Aaron P. Thrift, Theresa Nguyen Wenker, Hashem B. El-Serag
Nature Reviews Clinical Oncology.2023; 20(5): 338. CrossRef
Atrophic Gastritis and Autoimmunity: Results from a Prospective, Multicenter Study
Malgorzata Osmola, Caroline Hemont, Nicolas Chapelle, Marie-Anne Vibet, David Tougeron, Driffa Moussata, Dominique Lamarque, Edith Bigot-Corbel, Damien Masson, Justine Blin, Maxime Leroy, Regis Josien, Jean-François Mosnier, Jérôme Martin, Tamara Matysiak
Diagnostics.2023; 13(9): 1599. CrossRef
Epstein–Barr virus positive gastric adenocarcinoma with systemic EBV reactivation in a patient with persistently active systemic lupus erythematosus
Rada Miskovic, Danijela Miljanovic, Maja Dimic Cumic, Ivana Lazarevic, Ana Banko
Oncologie.2023; 25(1): 93. CrossRef
Dual direction associations between common autoimmune diseases and leukemia among children and young adults: A systematic review
Julia Ventelä, Anni Alanko, Anssi Auvinen, Olli Lohi, Atte Nikkilä
Cancer Epidemiology.2023; 86: 102411. CrossRef
Latin American and the Caribbean Code Against Cancer 1st edition: Infections and cancer
Rolando Herrero, Loretto J. Carvajal, M. Constanza Camargo, Arnoldo Riquelme, Carolina Porras, Ana Patricia Ortiz, Luis Aranha Camargo, Valeria Fink, Vanessa van De Wyngard, Eduardo Lazcano-Ponce, Carlos Canelo-Aybar, Graciela Balbin-Ramon, Ariadna Feliu,
Cancer Epidemiology.2023; 86: 102435. CrossRef
Association between Gastric Cancer and 12 Autoimmune Diseases: A Mendelian Randomization Study
Qi Wei, Ziyu Wang, Xuanyu Liu, Haibin Liang, Lei Chen
Genes.2023; 14(10): 1844. CrossRef
The risk of malignancy in patients with IgG4-related disease: a systematic review and meta-analysis
Tingfeng Yu, Yaxian Wu, Jia Liu, Yanyan Zhuang, Xiaoyan Jin, Lingyun Wang
Arthritis Research & Therapy.2022;[Epub] CrossRef
Associations Between Autoimmune Conditions and Gastric Cancer Risk Among Elderly Adults in the United States
Minkyo Song, M. Constanza Camargo, Andriy Derkach, Charles S. Rabkin, Eric A. Engels
American Journal of Gastroenterology.2022; 117(3): 486. CrossRef
IgG4-Related Disease With Gastrointestinal Involvement: Case Reports and Literature Review
Xinhe Zhang, Xing Jin, Lin Guan, Xuyong Lin, Xuedan Li, Yiling Li
Frontiers in Immunology.2022;[Epub] CrossRef
Autoimmungastritis
Marino Venerito, Sabrina Sulzer, Dörthe Jechorek
DMW - Deutsche Medizinische Wochenschrift.2022; 147(08): 451. CrossRef
Rare case of pernicious anaemia from a university hospital of Nepal: A case report
Suyesh Raj Shrestha, Pramit Ram Shrestha, Abhyuday Kumar Yadav, Sneha Shrestha, Ashish Shrestha, Pawan Katwal
Annals of Medicine and Surgery.2022; 80: 104151. CrossRef
Academy of Medicine, Singapore clinical guideline on endoscopic surveillance and management of gastric premalignant lesions
Vikneswaran Namasivayam, Calvin J Koh, Stephen Tsao, Jonathan Lee, Khoon Lin Ling, Christopher Khor, Tony Lim, James Weiquan Li, Aung Myint Oo, Benjamin CH Yip, Ikram Hussain, Tju Siang Chua, Bin Chet Toh, Hock Soo Ong, Lai Mun Wang, Jimmy BY So, Ming Teh
Annals of the Academy of Medicine, Singapore.2022; 51(7): 417. CrossRef
Sex differences in cancer incidence and mortality among patients managed at King Hussein Cancer Center
Abdallah Al‐Ani, Justin Z. Amarin, Leen Al‐Huneidy, Maysa Al‐Hussaini
International Journal of Cancer.2022; 151(11): 1960. CrossRef
Feasibility of ERAS in Patients With Gastric Cancer Complicated by Diabetes Mellitus
Ying Wang, He Han, Said Abdulrahman Salim Mzee, Deqian Wang, Jixiang Chen, Xin Fan
Technology in Cancer Research & Treatment.2022;[Epub] CrossRef
Research priorities in pernicious anaemia: James Lind Alliance Priority Setting Partnership
Kristina Staley, Kourosh R Ahmadi, Karyl Carter, Katherine Cowan, Heidi Seage, Petra Visser, Nicola Ward, Martyn Hooper
BMJ Open.2022; 12(8): e065166. CrossRef
Treatment of gastric cancer with dermatomyositis as the initial symptom: Two case reports and review of literature
Xiang-Fei Sun, Xiao-Dong Gao, Kun-Tang Shen
World Journal of Clinical Cases.2022; 10(27): 9727. CrossRef
The Diagnostic Value of Anti-Parietal Cell and Intrinsic Factor Antibodies, Pepsinogens, and Gastrin-17 in Corpus-Restricted Atrophic Gastritis
Petra Kriķe, Zakera Shums, Inese Poļaka, Ilze Kikuste, Aigars Vanags, Ivars Tolmanis, Sergejs Isajevs, Inta Liepniece-Karele, Daiga Santare, Lilian Tzivian, Dace Rudzīte, Minkyo Song, M. Constanza Camargo, Gary L. Norman, Mārcis Leja
Diagnostics.2022; 12(11): 2784. CrossRef
Cancer incidence and factors associated with malignancies in coeliac disease during long‐term follow‐up
Inka Koskinen, Kaisa Hervonen, Eero Pukkala, Timo Reunala, Katri Kaukinen, Pekka Collin
GastroHep.2021; 3(2): 107. CrossRef
Acute myelomonocytic leukaemia and pernicious anaemia in a patient with systemic lupus erythematosus: a rare coexistence of three immunological disorders
Francisco Espinoza-Gomez, Hector Carranza-Garcia, Estefania Velasco-Ibarra
British Journal of Hospital Medicine.2021; 82(5): 1. CrossRef
Autoimmunity as an Etiological Factor of Cancer: The Transformative Potential of Chronic Type 2 Inflammation
Chris M. Li, Zhibin Chen
Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef
The Relationship between Diabetes Mellitus and Gastric Cancer and the Potential Benefits of Metformin: An Extensive Review of the Literature
Chin-Hsiao Tseng
Biomolecules.2021; 11(7): 1022. CrossRef
Autoimmune disease and oral squamous cell carcinoma: A systematic review
Anjali Pillai, Dauren Adilbay, Konstantina Matsoukas, Ian Ganly, Snehal G. Patel
Journal of Oral Pathology & Medicine.2021; 50(9): 855. CrossRef
Can Cancer Patients With Autoimmune Diseases Use Immunotherapy?
Yefei Shu
American Journal of Clinical Oncology.2021; 44(8): 442. CrossRef
Autoimmune gastritis, with or without pernicious anemia: epidemiology, risk factors, and clinical management
Sheila D. Rustgi, Priyesha Bijlani, Shailja C. Shah
Therapeutic Advances in Gastroenterology.2021;[Epub] CrossRef
Clinicopathological characteristics of early gastric cancer associated with autoimmune gastritis
Shinji Kitamura, Naoki Muguruma, Koichi Okamoto, Kaizo Kagemoto, Yoshifumi Kida, Yasuhiro Mitsui, Hiroyuki Ueda, Tomoyuki Kawaguchi, Hiroshi Miyamoto, Yasushi Sato, Rika Aoki, Joji Shunto, Yoshimi Bando, Tetsuji Takayama
JGH Open.2021; 5(10): 1210. CrossRef
Six Autoimmune Disorders Are Associated With Increased Incidence of Gastric Cancer: A Systematic Review and Meta-Analysis of Half a Million Patients
Noémi Zádori, Lajos Szakó, Szilárd Váncsa, Nóra Vörhendi, Eduard Oštarijaš, Szabolcs Kiss, Levente Frim, Péter Hegyi, József Czimmer
Frontiers in Immunology.2021;[Epub] CrossRef
Autoimmune Gastritis in Pediatrics
Tania Mitsinikos, Nick Shillingford, Harry Cynamon, Vrinda Bhardwaj
Journal of Pediatric Gastroenterology and Nutrition.2020; 70(2): 252. CrossRef
AGA Technical Review on Gastrointestinal Evaluation of Iron Deficiency Anemia
Don C. Rockey, Osama Altayar, Yngve Falck-Ytter, Denise Kalmaz
Gastroenterology.2020; 159(3): 1097. CrossRef
Cancer risk in systemic sclerosis: identifying risk and managing high-risk patients
George E. Fragoulis, Dimitris Daoussis, Eleni Pagkopoulou, Alexandros Garyfallos, George D. Kitas, Theodoros Dimitroulas
Expert Review of Clinical Immunology.2020; 16(12): 1105. CrossRef
///
ii ivanov
Medicine of Extreme Situations.2020;[Epub] CrossRef
Role of heredity, endogenous and exogenous factors in gastric cancer
PV Ershov
Medicine of Extreme Situations.2020;[Epub] CrossRef
Editorial: determinants of diagnostic delay in autoimmune atrophic gastritis—a salutary lesson
Marjorie M. Walker
Alimentary Pharmacology & Therapeutics.2019; 50(4): 458. CrossRef
Functional Dyspepsia in the Elderly
Marjorie M. Walker, Nicholas J. Talley
Current Gastroenterology Reports.2019;[Epub] CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Autoimmune Diseases and Gastric Cancer Risk: A Systematic Review and Meta-Analysis

Cancer Res Treat. 2019;51(3):841-850. Published online May 3, 2019

DOI: https://doi.org/10.4143/crt.2019.151

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Electronic Supplementary Material
NOTES
REFERENCES

Autoimmune Diseases and Gastric Cancer Risk: A Systematic Review and Meta-Analysis

Fig. 1. Random effects summary relative risk (RR) and 95% confidence interval (CI) for gastric cancer among individuals with pernicious anemia [11,12,17-28].

Fig. 2. Random effects summary relative risk (RR) and 95% confidence interval (CI) for gastric cancer among individuals with diabetes mellitus type 1 [11,29-34].

Fig. 3. Random effects summary relative risk (RR) and 95% confidence interval (CI) for gastric cancer among individuals with systemic lupus erythematosus [11,12,35-37].

Fig. 1.

Fig. 2.

Fig. 3.

Autoimmune Diseases and Gastric Cancer Risk: A Systematic Review and Meta-Analysis

Autoimmune disease	Studies included for analysis	Gastric cancer cases	Summary RR	95% CI	Cochran Q statistic (p_{heterogeneity})	Higgin’s I² statistics	Egger test p-value	Studies imputed by trim and fill
Individual diagnoses
Addison disease	2	20	2.11	1.26-3.53	1.26 (0.26)	20.5	-	0
Amyotrophic lateral sclerosis	2	13	0.93	0.53-1.62	0.01 (0.93)	0	-	1
Ankylosing spondylitis	2	34	1.01	0.72-1.42	0.21 (0.65)	0	-	0
Celiac disease	7	80	1.36	0.87-2.13	18.53 (< 0.001)	73	0.59	0
Chronic rheumatic heart disease	2	184	1.19	0.86-2.13	8.28 (< 0.001)	87.9	-	0
Crohn disease	3	60	0.87	0.68-1.12	0.24 (0.89)	0	0.91	0
Dermatitis herpetiformis	3	13	1.74	1.02-2.97	1.07 (0.59)	0	0.07	2
Dermatomyositis	4	11^a)	3.69	1.74-7.79	5.10 (0.16)	41.2	0.66	2^b)
Diabetes mellitus, type 1	9	256^a)	1.41	1.20-1.67	12.45 (0.13)	35.7	0.89	0^b)
Graves disease	3	120	1.27	1.06-1.52	0.81 (0.67)	0	0.09	0
IgG4-related disease	2	6	1.69	1.00-2.87	0.58 (0.45)	0	-	1
Immune thrombocytopenic purpura	2	15	1.32	0.26-6.70	9.03 (< 0.001)	88.9	-	1
Multiple sclerosis	2	30	0.64	0.45-0.92	0.47 (0.50)	0	-	0
Pernicious anemia	14	2,688	2.84	2.30-3.50	73.98 (< 0.001)	82.4	0.32	0^b)
Polymyositis	2	2	0.82	0.12-5.55	2.30 (0.13)	56.6	-	0
Polymyositis/Dermatomyositis	2	7	1.15	0.16-8.25	4.42 (0.04)	77.4	-	0
Primary biliary cirrhosis	4	28	1.64	1.13-2.37	0.32 (0.96)	0	0.66	1
Psoriasis	2	128	1.18	0.98-1.14	0.58 (0.45)	0	-	1
Rheumatoid arthritis	10	388	0.93	0.82-1.07	15.78 (0.07)	43.0	0.38	1
Sarcoidosis	2	36	1.00	0.41-2.44	3.75 (0.05)	73.4	-	0
Sjögren syndrome	4	27^a)	1.33	0.99-1.79	3.15 (0.37)	4.6	0.05	1
Systemic lupus erythematosus	6	35^a)	1.37	1.01-1.84	4.85 (0.30)	17.6	0.12	0^b)
Systemic sclerosis	5	12^a)	0.93	0.58-1.48	0.56 (0.97)	0	0.74	0
Ulcerative colitis	3	45	0.94	0.70-1.26	0.95 (0.62)	0	0.27	0
Grouped diagnoses^c)
Autoimmune thyroid disease		163	1.31	1.12-1.54	3.84 (0.43)	0	0.77	0
Inflammatory bowel disease		105^a)	0.89	0.74-1.07	1.19 (0.93)	0	0.34	0
Polymyositis/Dermatomyositis		20^a)	2.09	1.04-4.20	17.59 (0.01)	60.2	0.10	0
Polymyalgia rheumatica/Giant cell arteritis		202	1.33	1.16-1.52	0.78 (0.38)	0	-	1
Vasculitides		38	1.03	0.75-1.41	1.89 (0.60)	0	0.84	0
Alimentary tract involving autoimmune diseases other than pernicious anemia		391^a)	1.18	1.04-1.33	60.16 (0.01)	36.8	0.86	0^b)
Non-alimentary tract involving autoimmune diseases		1,736^a)	1.21	1.10-1.34	182.77 (< 0.001)	67.7	0.43	10^b)
Endocrine organ autoimmune diseases		521^a)	1.42	1.25-1.61	21.39 (0.13)	29.9	0.65	0^b)
Non-endocrine organ autoimmune diseases other than pernicious anemia		1,607^a)	1.15	1.06-1.26	202.72 (< 0.001)	59.6	0.51	9^b)
Any autoimmune disease other than pernicious anemia		627^a)	1.20	1.11-1.30	243.13 (< 0.001)	59.7	0.60	9^b)
Any autoimmune disease		3,315^a)	1.37	1.24-1.52	685.72 (< 0.001)	83.7	0.18	0^b)

Disease	Exposed persons	Gastric cancer persons	Reported association
Autoimmune pancreatitis type 1	109	3	1.35 (0.03-2.66)
ANCA associated vasculitis: GPA and MPA^a)	203	1	2.37 (0.06-13.2)
Alopecia areata	12,199	39	0.46 (0.33-0.65)
Autoimmune hemolytic anemia	NR	6	1.10 (0.46-2.65)
Autoimmune thyroid disease^a)	23	17	3.16 (1.14-8.71)
Behçet disease	2,860	11	1.66 (0.83-2.99)
	1,620	0	NR
Discoid lupus erythematosus	NR	9	0.95 (0.48-1.90)
Hashimoto/hypothyroidism^a)	10,682	26	1.34 (0.87-1.96)
Inflammatory bowel disease^a)	2,853	NR	0.53 (0.13-2.11)
Kawasaki disease	3,463	0	NR
Localized scleroderma	3,128	11	1.56 (0.70-2.55)
	NR	0	NR
Membranous nephropathy	161	1	2.74 (0.07-15.3)
Myasthenia gravis	17,974	117	1.38 (1.14-1.65)
	NR	0	NR
Polyarteritis nodosa	12,046	35	1.02 (0.71-1.42)
	NR	0	NR
Polymyalgia rheumatica^a)	14,745	63	1.45 (1.11-1.85)
	NR	0	NR
Polymyalgia rheumatica/Giant cell arteritis^a)	35,918	139	1.27 (1.07-1.50)
Reactive arthritis	NR	0	NR
Rheumatic fever	3,458	16	1.50 (0.86-2.44)
	NR	0	NR
Takayasu arteritis	180	1	1.4 (0.0-7.3)
Vasculitis excluding Kawasaki disease	644	0	NR
Wegener granulomatosis^a)	345	1	0.45 (0.0-2.59)

Table 1. Random effects summary relative risk (RR) and 95% confidence interval (CI) of gastric cancer for persons with autoimmune disease

One or more studies did not provide number of cases,

Retained significance after trim and fill imputation,

Grouped diagnoses definitions (numbers of studies included): autoimmune thyroid disease: autoimmune thyroid disease (1), Graves disease (3), Hashimoto/hypothyroidism (1); inflammatory bowel disease: Crohn disease (3), inflammatory bowel disease (1), ulcerative colitis (3); polymyositis/dermatomyositis: dermatomyositis (2), polymyositis (1), polymyositis/dermatomyositis (1); polymyalgia rheumatica/giant cell arteritis: polymyalgia rheumatica (1), polymyalgia rheumatica/giant cell arteritis (1); vasculitides: antineutrophil cytoplasmic antibody associated vasculitis (1), polyarteritis nodosa (1), Takayasu arteritis (1), Wegener granulomatosis (1); alimentary tract involving autoimmune diseases: ankylosing spondylitis (2), celiac disease (7), Crohn disease (3), discoid lupus erythematosus (1), immune thrombocytopenic purpura (2), inflammatory bowel disease (1), localized scleroderma (1), pernicious anemia (16), primary biliary cirrhosis (4), sarcoidosis (2), Sjögren syndrome (4), systemic lupus erythematosus (7), systemic sclerosis (5), ulcerative colitis (3); endocrine organ autoimmune diseases: Addison disease (2), autoimmune thyroid disease (5), diabetes mellitus, type 1 (11); any autoimmune disease: includes all diagnoses listed in Tables 1 or 2.

Table 2. Reported associations of gastric cancer with autoimmune diseases from single studies

ANCA, antineutrophil cytoplasmic antibody; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiits; NR, not reported.

Also included in Table 1 grouped diagnoses.